AstraZeneca Reaffirms FY26 Outlook: Sees Total Rev Up Mid-To-High Single-Digit %, Core EPS Up Low Double-Digit % At CER
Share
Why It Matters
AstraZeneca said its money growth will stay on track next year. That means the company feels confident about its business right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.